<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35962027</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Deep learning methods to predict amyotrophic lateral sclerosis disease progression.</ArticleTitle><Pagination><StartPage>13738</StartPage><MedlinePgn>13738</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13738</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-17805-9</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a highly complex and heterogeneous neurodegenerative disease that affects motor neurons. Since life expectancy is relatively low, it is essential to promptly understand the course of the disease to better target the patient's treatment. Predictive models for disease progression are thus of great interest. One of the most extensive and well-studied open-access data resources for ALS is the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) repository. In 2015, the DREAM-Phil Bowen ALS Prediction Prize4Life Challenge was held on PRO-ACT data, where competitors were asked to develop machine learning algorithms to predict disease progression measured through the slope of the ALSFRS score between 3 and 12&#xa0;months. However, although it has already been successfully applied in several studies on ALS patients, to the best of our knowledge deep learning&#xa0;approaches still remain unexplored on the ALSFRS slope prediction in PRO-ACT cohort. Here, we investigate how deep learning models perform in predicting ALS progression using the PRO-ACT data. We developed three models based on different architectures that showed comparable or better performance with respect to the state-of-the-art models, thus representing a valid alternative to predict ALS disease progression.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Pancotti</LastName><ForeName>Corrado</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Turin, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Birolo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Turin, 10126, Turin, Italy. giovanni.birolo@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rollo</LastName><ForeName>Cesare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Turin, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanavia</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Turin, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Camillo</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Information Engineering, University of Padua, 35131, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>ALS Center, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Center, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fariselli</LastName><ForeName>Piero</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Turin, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="Y">Deep Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35962027</ArticleId><ArticleId IdType="pmc">PMC9374680</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-17805-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-17805-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wijesekera LC, Nigel Leigh P. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009;4:1&#x2013;22. doi: 10.1186/1750-1172-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Van Den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:639&#x2013;649. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, El Munsat TL. escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon, G., Lacomblez, L., Meininger, V. &amp; Group, A. S A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012;2:CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielska E, et al. Oxidative stress in neurodegenerative diseases. Mol. Neurobiol. 2016;53:4094&#x2013;4125. doi: 10.1007/s12035-015-9337-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9337-5</ArticleId><ArticleId IdType="pmc">PMC4937091</ArticleId><ArticleId IdType="pubmed">26198567</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilio F, et al. Botulinum toxin type a for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study. Amyotroph. Lateral Scler. 2010;11:359&#x2013;363. doi: 10.3109/17482960903264998.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903264998</ArticleId><ArticleId IdType="pubmed">19929745</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromol. Med. 2008;10:275&#x2013;290. doi: 10.1007/s12017-008-8053-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-008-8053-y</ArticleId><ArticleId IdType="pmc">PMC2886719</ArticleId><ArticleId IdType="pubmed">19005780</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroscio, J. Prognostic factors in motor neuron disease: A prospective study of longevity. Research progress in motor neuron disease 34&#x2013;43 (1984).</Citation></Reference><Reference><Citation>Louwerse E, Visser C, Bossuyt P, Weverling G, et al. Amyotrophic lateral sclerosis: Mortality risk during the course of the disease and prognostic factors. J. Neurol. Sci. 1997;152:s10&#x2013;s17. doi: 10.1016/S0022-510X(97)00238-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00238-4</ArticleId><ArticleId IdType="pubmed">9419048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Preux P-M, et al. Survival prediction in sporadic amyotrophic lateral sclerosis. Neuroepidemiology. 1996;15:153&#x2013;160. doi: 10.1159/000109902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000109902</ArticleId><ArticleId IdType="pubmed">8700307</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes RB, Colville S, Swingler RJ. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing. 2004;33:131&#x2013;134. doi: 10.1093/ageing/afh013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afh013</ArticleId><ArticleId IdType="pubmed">14960427</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Aguila M, Longstreth W, McGuire V, Koepsell T, Van Belle G. Prognosis in amyotrophic lateral sclerosis: A population-based study. Neurology. 2003;60:813&#x2013;819. doi: 10.1212/01.WNL.0000049472.47709.3B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000049472.47709.3B</ArticleId><ArticleId IdType="pubmed">12629239</ArticleId></ArticleIdList></Reference><Reference><Citation>Tysnes O-B, Vollset S, Aarli J. Epidemiology of amyotrophic lateral sclerosis in Hordaland county, Western Norway. Acta Neurol. Scand. 1991;83:280&#x2013;285. doi: 10.1111/j.1600-0404.1991.tb04701.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1991.tb04701.x</ArticleId><ArticleId IdType="pubmed">2063649</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch. Neurol. 2000;57:1171&#x2013;1176. doi: 10.1001/archneur.57.8.1171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.8.1171</ArticleId><ArticleId IdType="pubmed">10927797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N. Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials. J. Neurol. Sci. 1997;152:s1&#x2013;s9. doi: 10.1016/S0022-510X(97)00237-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00237-2</ArticleId><ArticleId IdType="pubmed">9419047</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, et al. Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V, et al. Manifold learning for amyotrophic lateral sclerosis functional loss assessment. J. Neurol. 2021;268:825&#x2013;850. doi: 10.1007/s00415-020-10181-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10181-2</ArticleId><ArticleId IdType="pubmed">32886252</ArticleId></ArticleIdList></Reference><Reference><Citation>Faghri F, et al. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: A population-based machine-learning study. Lancet Digit. Health. 2022;4:e359&#x2013;e369. doi: 10.1016/S2589-7500(21)00274-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(21)00274-0</ArticleId><ArticleId IdType="pmc">PMC9038712</ArticleId><ArticleId IdType="pubmed">35341712</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavazzi E, et al. Predicting functional impairment trajectories in amyotrophic lateral sclerosis: A probabilistic, multifactorial model of disease progression. J. Neurol. 2022;269:3858&#x2013;3878. doi: 10.1007/s00415-022-11022-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11022-0</ArticleId><ArticleId IdType="pmc">PMC9217910</ArticleId><ArticleId IdType="pubmed">35266043</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, et al. The PRO-ACT database: Design, initial analyses, and predictive features. Neurology. 2014;83:1719&#x2013;1725. doi: 10.1212/WNL.0000000000000951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000951</ArticleId><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;ffner R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat. Biotechnol. 2015;33:51&#x2013;57. doi: 10.1038/nbt.3051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3051</ArticleId><ArticleId IdType="pubmed">25362243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kueffner R, et al. Stratification of amyotrophic lateral sclerosis patients: A crowdsourcing approach. Sci. Rep. 2019;9:1&#x2013;14. doi: 10.1038/s41598-018-36873-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-36873-4</ArticleId><ArticleId IdType="pmc">PMC6345935</ArticleId><ArticleId IdType="pubmed">30679616</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiman L. Random forests. Mach. Learn. 2001;45:5&#x2013;32. doi: 10.1023/A:1010933404324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1010933404324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hearst MA, Dumais ST, Osuna E, Platt J, Scholkopf B. Support vector machines. IEEE Intell. Syst. Appl. 1998;13:18&#x2013;28. doi: 10.1109/5254.708428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/5254.708428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hothorn T, Jung HH. RandomForest4Life: A random forest for predicting ALS disease progression. Amyotroph. Lateral Scler. Frontotemporal Degener. 2014;15:444&#x2013;452. doi: 10.3109/21678421.2014.893361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.893361</ArticleId><ArticleId IdType="pubmed">25141076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M, et al. Model-based and model-free techniques for amyotrophic lateral sclerosis diagnostic prediction and patient clustering. Neuroinformatics. 2019;17:407&#x2013;421. doi: 10.1007/s12021-018-9406-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-018-9406-9</ArticleId><ArticleId IdType="pmc">PMC6527505</ArticleId><ArticleId IdType="pubmed">30460455</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burgh HK, et al. Deep learning predictions of survival based on MRI in amyotrophic lateral sclerosis. NeuroImage Clin. 2017;13:361&#x2013;369. doi: 10.1016/j.nicl.2016.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.10.008</ArticleId><ArticleId IdType="pmc">PMC5219634</ArticleId><ArticleId IdType="pubmed">28070484</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin B, et al. Using the structure of genome data in the design of deep neural networks for predicting amyotrophic lateral sclerosis from genotype. Bioinformatics. 2019;35:i538&#x2013;i547. doi: 10.1093/bioinformatics/btz369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz369</ArticleId><ArticleId IdType="pmc">PMC6612814</ArticleId><ArticleId IdType="pubmed">31510706</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengur A, Akbulut Y, Guo Y, Bajaj V. Classification of amyotrophic lateral sclerosis disease based on convolutional neural network and reinforcement sample learning algorithm. Health Inf. Sci. Syst. 2017;5:1&#x2013;7. doi: 10.1007/s13755-017-0029-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13755-017-0029-6</ArticleId><ArticleId IdType="pmc">PMC5662529</ArticleId><ArticleId IdType="pubmed">29142739</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M, Gromicho M, de Carvalho M, Madeira SC. Explainable models of disease progression in ALS: Learning from longitudinal clinical data with recurrent neural networks and deep model explanation. Comput. Methods Programs Biomed. Update. 2021;1:100018. doi: 10.1016/j.cmpbup.2021.100018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpbup.2021.100018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitinck, L. et&#xa0;al. API design for machine learning software: Experiences from the scikit-learn project. In ECML PKDD Workshop: Languages for Data Mining and Machine Learning 108&#x2013;122 (2013).</Citation></Reference><Reference><Citation>Lundberg SM, Lee S-I, et al. A unified approach to interpreting model predictions. In: Guyon I, et al., editors. Advances in Neural Information Processing Systems. Curran Associates Inc.; 2017. pp. 4765&#x2013;4774.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>